Jemperli’s was approved for the first-line ... RUBY to see if overall survival data will support an ‘all-comer’ label in future. GSK views the endometrial cancer indication as a catalyst ...

The label change also comes after GSK voluntarily ... including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others targeting TIM-3 and LAG-3 checkpoints. Sales of the drug have failed ...

The approval covers Jemperli's use in combination with chemotherapy. Late last year, Europe's Committee for Medicinal Products for Human Use (CHMP) recommended the label expansion. The ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed last ...

Teva Pharmaceutical Industries Ltd. ADR 0.46% $24.53B ...